Astellas Pharma Inc.
ALPMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.18B
Close$
$47.32
171.9% upside
Current Fair Value
171.9% upsideUndervalued by 171.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $31.18 Billion |
|---|---|
| Enterprise Value | $374.07 Billion |
| Annual dividend | $0.50 |
| Dividend yield | 3.14% |
| Earnings per Share | $164.57 |
| Beta | 0.09 |
| Outstanding Shares | 1,791,933,000 |
Return
| Return on Equity | 15.76% |
|---|---|
| Return on Assets | 8.29% |
| Return on Invested Capital | 17.25% |
Valuation & Multiples
| P/E Ratio | 12.33 |
|---|---|
| PEG | 11.23 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | 0.2 |
| Enterprise Value to EBIT | 0.89 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.57 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.33
Consensus analyst estimateRevenue Estimate
$3.44 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.41
Consensus analyst estimateRevenue Estimate
$3.76 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Astellas Pharma Inc.
14,099 employees
CEO: Kenji Yasukawa
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. ...